The neuroprotective and axogenic effects of PACAP have been proven in numerous animal models of neurological diseases, such as cerebral ischemia, Alzheimer’s disease, and traumatic brain injury (Han et al., 2014; Matsumoto et al., 2016; Toth et al., 2020). Here, ADCYAP1 is linked to Alzheimer disease.